Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)

View Full Paper
Ask AI
Bookmark
Share

Authors

SZS. ZhangYXYan XuDZDehui Zou

Discussion

Loading...

Member takes

Overview

Phase II trial shows high complete response rates in marginal zone lymphoma patients, indicating potential as a first-line treatment.

Key Points

  • Adverse events primarily included grade 1-2 hematological toxicities, indicating manageable safety profile.
  • With a median follow-up of 4.6 months, the treatment shows promise for marginal zone lymphoma.
  • The regimen achieved a 72% complete response rate among efficacy-evaluable patients, suggesting effectiveness.
  • This approach may enable chemotherapy-free treatment options for patients with treatment-naïve marginal zone lymphoma.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236e016https://doi.org/10.1182/blood-2025-5379
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Efficacy, safety, and NGS analysis of orelabrutinib combined with obinutuzumab in untreated marginal zone lymphoma2025
  2. 2Efficacy and safety of first-line orelabrutinib combined with obinutuzumab (With or Without Bendamustine) in high-risk marginal zone lymphoma: Results from the orchid study2025
  3. 3Preliminary study results of orelabrutinib in combination with rituximab for treatment-Naïve marginal zone lymphoma: A prospective single-arm clinical trial2025 · 1 citations
  4. 4Orelabrutinib combined with bendamustine-rituximab or obinutuzumab followed by orelabrutinib maintenance in untreated marginal zone lymphoma (Optimize): A multicenter, single-arm, phase II study2025 · 1 citations
  5. 5Real-world efficacy and safety of orelabrutinib-based regimens in the treatment of marginal zone lymphoma2025